Jahn M. Nesland
- Oncology top 0.5%
- Cancer-related Molecular Pathways 30
- Cancer Cells and Metastasis 23
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism 17
- Pulmonary and Respiratory Medicine top 0.5%
- Photodynamic Therapy Research Studies 24
- Sarcoma Diagnosis and Treatment 14
- Molecular Biology top 1%
- Cancer-related gene regulation 13
- Pathology and Forensic Medicine top 0.5%
-
- Cancer Research and Treatments 16
-
- Nanoplatforms for cancer theranostics 15
Jahn M. Nesland
201 papers receiving 11.2k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 4.5k
- Cancer Research 2.3k
- Pulmonary and Respiratory Medicine 3.0k
- Molecular Biology 5.5k
- Pathology and Forensic Medicine 1.3k
Countries citing papers authored by Jahn M. Nesland
This map shows the geographic impact of Jahn M. Nesland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jahn M. Nesland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jahn M. Nesland more than expected).
Fields of papers citing papers by Jahn M. Nesland
This network shows the impact of papers produced by Jahn M. Nesland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jahn M. Nesland. The network helps show where Jahn M. Nesland may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jahn M. Nesland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 28 | |
| 2 | 2013 | 26 | |
| 3 | 2013 | 14 | |
| 4 | 2013 | 15 | |
| 5 | 2013 | 14 | |
| 6 | 2012 | 18 | |
| 7 | 2012 | 104 | |
| 8 | 2010 | 40 | |
| 9 | 2010 | 40 | |
| 10 | 2009 | 35 | |
| 11 | 2009 | 295 | |
| 12 | 2005 | 165 | |
| 13 | 2005 | 71 | |
| 14 | DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisbreakdown → | 2005 | 2117 |
| 15 | Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. | 2002 | 16 |
| 16 | 2001 | 19 | |
| 17 | 2000 | 21 | |
| 18 | 1998 | 17 | |
| 19 | 1993 | 25 | |
| 20 | 1990 | 46 |
About Jahn M. Nesland
Jahn M. Nesland is a scholar working on Cancer Research, Oncology and Biotechnology, having authored 203 papers that have together received 11.4k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (30 papers), Photodynamic Therapy Research Studies (24 papers), Cancer Cells and Metastasis (23 papers), Cancer, Hypoxia, and Metabolism (17 papers), Cancer Research and Treatments (16 papers), Nanoplatforms for cancer theranostics (15 papers), Sarcoma Diagnosis and Treatment (14 papers) and Cancer-related gene regulation (13 papers). The work is most often cited by research in Oncology (4.5k citations), Cancer Research (2.3k citations) and Pulmonary and Respiratory Medicine (3.0k citations). Jahn M. Nesland has collaborated with scholars based in Norway, China and United States. Frequent co-authors include Qian Peng, Ruth Holm, Johan Moan, Zhenhe Suo, Zuzana Hořejšı́, Jiří Bártek, Jiřina Bártková, Maxwell Sehested, I. K. Bukholm and Alwin Krämer. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.